Schedule 1  s 2(1)

Class A controlled drugs

1 The following substances, namely:

- **Acetorphine** (\(\theta^3\)-acetyl-7,8-dihydro-7 \(\alpha\)-[1 \((R)\)-hydroxy-1-methylbutyl]-\(\theta^6\)-methyl-6,14-endoethenomorphine)
- **Bufotenine** (3-(2-dimethylaminoethyl)-5-hydroxyindole)
- **Cantharidin** (hexahydro-3a,7a-dimethyl-4,7-epoxyisobenzofuran-1,3-dione)
- **Cocaine** (methyl ester of benzoylecgonine), except when contained in a Class C controlled drug
- **Desomorphine** (dihydrodeoxymorphine)
- **DET** \((N,N\)-diethyltryptamine\)
- **DMA** (2-amino-1-(2,5-dimethoxyphenyl)propane)
- **DMHP** (3-(1,2-dimethylheptyl)-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo \([b,d]\) pyran)
- **DMT** \((N,N\)-dimethyltryptamine\)
- **DOB** (2-amino-1-(4-bromo-2,5-dimethoxyphenyl)propane) (also known as bromo-DMA)
- **Etorphine** (7,8-dihydro-7 \(\alpha\)-[1 \((R)\)-hydroxy-1-methylbutyl]-\(\theta^6\)-methyl-6,14-endoethenomorphine)
- **Heroin** (diacetylmorphine)
- **Ketobemidone** (4-meta-hydroxyphenyl-1-methyl-4-propionylpiperidine)
- **Lysergic acid** (essential precursor for manufacture of LSD)
- **Lysergide** \((N,N\)-diethyllysergamide or lysergic acid diethylamide\)
- **MDA** (2-amino-1-(3,4-methylenedioxyphenyl) propane)
- **Mescaline** (3,4,5-trimethoxyphenethylamine)
- **Methamphetamine** (2-methylamino-1-phenylpropane)
- **5-methoxydimethyltryptamine** (5-methoxy-\(N,N\)-dimethyltryptamine)
- **2-methoxy-4,5-methylenedioxyamphetamine** (2-amino-1-(2-methoxy-4,5-methylenedioxyphenyl) propane) (also known as MMDA or MMDA-2)
3-methoxy-4,5-methylenedioxyamphetamine (2-amino-1-(3-methoxy-4,5-methylenedioxyphenyl) propane) (also known as MMDA)
MPTP (1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine)
Parahexyl (3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo[b,d] pyran)
PCE (N-ethyl-1-phenylcyclohexylamine)
PCPY (1-(1-phenylcyclohexyl)pyrrolidine)
PEPTP (1-(2-phenylethyl)-4-phenyl-1,2,5,6-tetrahydropyridine)
Phencyclidine (1-(1-phenylcyclohexyl) piperidine)
PHP (1-(1-phenylcyclohexyl)pyrrolidine)
Piperidyl benzilates (N-methylpiperidyl benzilates and N-ethylpiperidyl benzilates but excluding the methobromide salts)
PMA (2-amino-1-(4-methoxyphenyl)propane)
Psilocine (3-(2-dimethylaminoethyl)-4-hydroxyindole)
Psilotsin (3-(2-dimethylaminoethyl)-4-hydroxyindole)
Psilocybine (3-(2-dimethylaminoethyl) indol-4-yl dihydrogen phosphate)
STP, DOM (2-amino-1-(2,5-dimethoxy-4-methyl phenylpropane)
TCP (1-[1-(2-thienyl)cyclohexyl]piperidine)
TMA (2-amino-1-(3,4,5-trimethoxyphenyl)propane).

Schedule 1 clause 1 4-bromo-2,5-dimethoxyamphetamine: repealed, on 2 September 1996, by section 6(1)(a) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).
Schedule 1 clause 1 Cocaine: inserted, on 13 January 1988, by section 8 of the Misuse of Drugs Amendment Act (No 2) 1987 (1987 No 193).
Schedule 1 clause 1 2,5-dimethoxyamphetamine: repealed, on 2 September 1996, by section 6(1)(b) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).
Schedule 1 clause 1 DMA: inserted, on 2 September 1996, by section 6(3) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).
Schedule 1 clause 1 Lysergic acid: inserted, on 2 September 1996, by section 6(3) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).
Schedule 1 clause 1 Methamphetamine: inserted, on 30 May 2003, by clause 4 of the Misuse of Drugs (Changes to Controlled Drugs) Order 2003 (SR 2003/47).

Schedule 1 clause 1 4-methoxyamphetamine: repealed, on 2 September 1996, by section 6(1)(c) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).

Schedule 1 clause 1 2-methoxy-4,5-methylenedioxyamphetamine: inserted, on 2 September 1996, by section 6(3) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).

Schedule 1 clause 1 3-methoxy-4,5-methylenedioxyamphetamine: substituted, on 2 September 1996, by section 6(2) of the Misuse of Drugs Amendment Act 1996 (1996 No 133).

Schedule 1 clause 1 MPTP: inserted, on 13 January 1988, by section 8 of the Misuse of Drugs Amendment Act (No 2) 1987 (1987 No 193).


Schedule 1 clause 1 PEPTP: inserted, on 13 January 1988, by section 8 of the Misuse of Drugs Amendment Act (No 2) 1987 (1987 No 193).


Schedule 1 clause 1 Thalidomide: repealed, on 9 August 2011, by section 7 of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).


2 The isomers of the substances mentioned in this schedule whenever the existence of such isomers is possible within the specific chemical designation.

3 The esters and ethers of the substances mentioned in this schedule and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.
4 The salts of the substances mentioned in this schedule and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4.
Schedule 2

Class B controlled drugs

Part 1

1 The following substances, namely:
   Amphetamine (2-amino-1-phenylpropane)
   Cannabis preparations: that is, any preparation containing any tetrahydrocannabinols, including cannabis resin (commonly known as hashish) and cannabis oil (commonly known as hash oil), produced by subjecting cannabis plant material to any kind of processing
   MDMA (2-methylamino-1-(3,4-methylenedioxyphenyl)propane)
   Methcathinone
   Morphine
   Opium
   Tetrahydrocannabinols, except when contained in a Class C controlled drug.


2 The isomers of the substances mentioned in clause 1 whenever the existence of such isomers is possible within the specific chemical designation.

Part 1—continued

3 The esters and ethers of the substances mentioned in clause 1 and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.


4 The salts of the substances mentioned in clause 1 and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.


5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4.

6 The substance gamma-hydroxybutyrate (GHB) (commonly known as fantasy) and—
(a) the esters, ethers, and amides of GHB; and
(b) all substances from which GHB can be derived, including (without limitation)—
(i) 1,4-butanediol:
(ii) gamma-aminobutyric acid:
(iii) gamma-butyrolactone:
(iv) gamma-hydroxybutyraldehyde; and
(c) the salts of GHB (including sodium oxybate) and the salts of any substance referred to in paragraph (a) or paragraph (b); and
(d) any substance, preparation, or mixture containing any proportion of GHB or any substance referred to in any of paragraphs (a) to (c).

Part 2

1 The following substances, namely:

- **Benzphetamine** (2-benzylmethylamino-1-phenylpropane)
- **Cathinone** (2-amino-1-phenylpropan-1-one)
- **DOET** (2-amino-1-(2,5-dimethoxy-4-ethylphenyl) propane)
- **Ephedrine**
- **N-ethyl MDA** (2-ethylamino-1-(3,4-methylene dioxyphenyl) propane)
- **N-ethylamphetetamine** (2-ethylamino-1-phenylpropane)
- **Fencamfamine** (N-ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine)
- **Fenethylline** (3,7-dihydro-1,3-dimethyl-7-[2-[(1-methyl-2-phenylethyl)-amino]ethyl]-1H-purine-2,6-dione)
- **Fenproporex** (2-(2-cyanoethylamino)-1-phenylpropane)
- **N-hydroxy MDA** (2-hydroxyamino-1-(3,4-methylene dioxyphenyl) propane)
- **Mefenorex** (2-(3-chloropropylamino)-1-phenylpropane)
- **Methaqualone** (2-methyl-3-(2-methylphenyl)-4(3H)-quinazolinone)
- **4-methylaminorex** (cis-2-amino-4-methyl-5-phenyl-2-oxazine)
- **Methylphenidate** (α-phenyl-2-piperidineacetic acid methyl ester)
- **4-methylthioamphetamine**
- **Norpseudoephedrine** (threo-2-amino-1-hydroxy-1-phenylpropane), including cathine
- **Propylhexedrine** (1-cyclohexyl-2-methylaminopropane)
- **Pseudoephedrine**
- **Pyrovalerone** (1-(4-methylphenyl)-2-(1-pyrrolidinyl)-1-pentanone).


Schedule 2 Part 2 clause 1 **Amphetamine**: repealed, on 9 September 2005, by clause 4(2) of the Misuse of Drugs (Changes to Controlled Drugs) Order 2005 (SR 2005/175).
Part 2—continued

Schedule 2 Part 2 clause 1 **Ephedrine**: inserted, on 8 September 2011, by section 8 of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).

Schedule 2 Part 2 clause 1 **N-ethyl MDA**: inserted, on 2 September 1996, by section 7(3) of the Misuse of Drugs Amendment Act 1996 (1966 No 133).

Schedule 2 Part 2 clause 1 **N-hydroxy MDA**: inserted, on 2 September 1996, by section 7(3) of the Misuse of Drugs Amendment Act 1996 (1966 No 133).

Schedule 2 Part 2 clause 1 **MDMA**: repealed, on 9 September 2005, by clause 4(2) of the Misuse of Drugs (Changes to Controlled Drugs) Order 2005 (SR 2005/175).

Schedule 2 Part 2 clause 1 **Norpseudoephedrine**: substituted, on 2 September 1996, by section 7(2) of the Misuse of Drugs Amendment Act 1996 (1966 No 133).

Schedule 2 Part 2 clause 1 **Pseudoephedrine**: inserted, on 8 September 2011, by section 8 of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).

2 The isomers of the substances mentioned in this Part whenever the existence of such isomers is possible within the specific chemical designation.

3 The esters and ethers of the substances mentioned in this Part and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.

4 The salts of the substances mentioned in this Part and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4.
Part 3

1 The following substances, namely:

- **Acetyl-α-methylfentanyl** \((N-[1-(α-methylphenethyl]-4-piperidyl] acetanilide)\)
- **Acetylmethadol** \((3\text{-acetox}-6\text{-dimethylamino}-4,4\text{-diphenylheptane})\)
- **Alfentanil** \((N-[1-(4\text{-ethyl}-4,5\text{-dihydro}-5\text{-oxo}-1H(tetrazol-1-yl)ethyl]-4-(methoxymethyl)-4\text{-piperidinyl}]-N\text{-phenylpropanamide})\)
- **Allylprodine** \((3\text{-allyl}-1\text{-methyl}-4\text{-phenyl}-4\text{-propionoxypiperidine})\)
- **Alphacetylmethadol** \(α\text{-3-acetox}-6\text{-dimethylamino-4,4-diphenylheptane})\)
- **Alphamepridine** \(α\text{-3-ethyl-1-methyl}-4\text{-phenyl-4-propionoxypiperidine})\)
- **Alphamethadol** \(α\text{-6-dimethylamino-4,4-diphenyl-3-heptanol})\)
- **Alphaprodine** \(α\text{-1,3-dimethyl-4-phenyl-4-propionoxypiperidine})\)
- **Anileridine** \((1\text{-para-aminophenethyl}-4\text{-phenylpiperidine-4-carboxylic acid ethyl ester})\)
- **Benzethidine** \((1\text{-2-benzylxyethyl}-4\text{-phenylpiperidine-4-carboxylic acid ethyl ester})\)
- **Benzylmorphine** \((3\text{-benzylmorphine})\)
- **Betacetylmethadol** \(β\text{-3-acetox}-6\text{-dimethylamino-4,4-diphenylheptane})\)
- **Betamethadol** \((β\text{-6-dimethylamino-4,4-diphenyl-3-heptanol})\)
- **Betaprodine** \((β\text{-1,3-dimethyl-4-phenyl-4-propionoxypiperidine})\)
- **Bezitramide** \((1\text{-3-cyano-3,3-diphenylpropyl}-4\text{-2-oxo-3-propionyl-1-benzimidazolyl)piperidine})\)
- **Clonitazene** \((2\text{-para-chlorbenzyl-1-diethylaminoethyl-5-nitrobenzimidazole})\)
- **Codoxime** \((\text{dihydrocodeinone-6-carboxymethylxime})\)
Part 3—continued

Concentrate of poppy straw—that is, the material arising when parts of any plant of the species *Papaver somniferum* have entered a process for the concentration of the alkaloids

Dextromoramide ((+)-4-[2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl) butyl] morpholine)

Diampromide (N-[2-(methylphenethylamino) propyl] propionanilide)

Diethylthiambutene  (3-diethylamino-1,1-di-(2'-thienyl)-1-butene).

Difenoxin  (1-(3-cyano-3, 3 diphenylpropyl)-4-phenylisonipecotic acid)

Dihydromorphone

Dimenoxadol (2-dimethylaminoethyl 1-ethoxy-1, 1-diphenylacetate)

Dimethylenepentanol (6-dimethylamo-4,4-diphenyl-3-heptanol)

Dimethylthiambutene  (3-dimethylamino-1,1-di-(2'-thienyl)-1-butene)

Dioxyphenyl butyrate  (ethyl 4-morpholino-2, 2-diphenylbutyrate)

Diphenoxylate  (1-(3-cyano-3,3-diphenylpropyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester)

Dipipanone (4,4-diphenyl-6-piperidine-3-heptanone)

Drotebanol  (3,4-dimethoxy-17-methylmorphinan-6β, 14-diol)

Ecgonine, its esters and derivatives which are convertible to ecgonine and cocaine, except when contained in a Class C controlled drug

Ethylmethylthiambutene  (3-ethylmethylamino-1,1-di-(2'-thienyl)-1-butene)

Etonitazene  (1-diethylaminoethyl-2-para-ethoxybenzyl-5-nitrobenzimidazole)

Etoxeridine  (1-[2-(2-hydroxyethoxy)ethyl]-4-phenylpiperidine-4-carboxylic acid ethyl ester)

Fentanyl (1-phenethyl-4-(N-propionylanilino)piperidine)
Part 3—continued

\textbf{p-fluorofentanyl} (4′-fluoro-N-1-(phenethyl-4-piperidyl) propionanilide)

\textbf{Furethidine} \quad \text{(1-(2-tetrahydrofurfuryloxyethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester)}

\textbf{Hydrocodone} (dihydrocodeine)

\textbf{Hydromorphinol} (14-hydroxydihydromorphine)

\textbf{Hydromorphone} (dihydromorphinone)

\textbf{β-hydroxyfentanyl} \quad \text{(N-[1-(β-hydroxyphenethyl)-4-piperidyl]propionanilide)}

\textbf{β-hydroxy-3-methylfentanyl} \quad \text{(N-[1-(β-hydroxyphenethyl)-3-methyl-4-piperidyl]propionanilide)}

\textbf{Hydroxypethidine} \quad \text{(4-meta-hydroxyphenyl-1-methylpiperidine-4-carboxylic acid ethyl ester)}

\textbf{Isomethadone} \quad \text{(6-dimethylamino-5-methyl-4,4-diphenyl-3-hexanone)}

\textbf{Levomethorphan} \quad \text{((−)-3-methoxy-N-methylmorphinan) but not including dextromethorphan ((+)-3-methoxy-N-methylmorphinan) and dextrophan ((+)-3-hydroxy-N-methylmorphinan)}

\textbf{Levomoramide} \quad \text{((−)-4-[2-methyl-4-oxo-3,3-diphenyl-4-(1-pyrrolidinyl) butyl] morpholine)}

\textbf{Levophenacylmorphan} \quad \text{((−)-3-hydroxy-N-phenacylmorphinan)}

\textbf{Levorphanol} \quad \text{((−)-3-hydroxy-N-methylmorphinan)}

\textbf{Mecloqualone} \quad \text{(3-(2-chlorophenyl)-2-methyl-4-(3H)-quazolinone)}

\textbf{Metazocine} \quad \text{(2′-hydroxy-2,5,9-trimethyl-6,7-benzomorphan)}

\textbf{Methadone} \quad \text{(6-dimethylamino-4,4-diphenyl-3-heptanone)}

\textbf{Methadone-intermediate} \quad \text{(4-cyano-2-dimethylamino-4,4-diphenylbutane)}

\textbf{1-methyl-4-phenyl-4-piperidinol}

\textbf{Methyldesorphine} \quad \text{(6-methyl-Δ^6-deoxymorphine)}

\textbf{Methyldihydromorphine} \quad \text{(6-methyldihydromorphine)}

\textbf{α-methylfentanyl} \quad \text{(N-[1-(α-methylphenethyl)-4-piperidyl]propionanilide)}
3-methylfentanyl (N-[3-methyl-1-phenethyl-4-piperidyl] propionanilide)
α-methylthiofentanyl (N-[1-[1-methyl-2-(2-thienyl)ethyl]-4-piperidyl]propionanilide)
3-methylthiofentanyl (N-[3-methyl-1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide)
Metopon (5-methylidihydromorphinone)
Moramide-intermediate (2-methyl-3-morpholino-1,1-diphenylpropane carboxylic acid)
Morpheridine (1-(2-morpholinoethyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Morphine methobromide and other pentavalent nitrogen morphine derivatives
Morphine-n-oxide
MPPP (1-methyl-4-phenyl-4-piperidinol propionate (ester))
Myrophenine (myristylbenzylmorphine)
Nabilone (trans-3-(1-1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6, 6-dimethyl-9H-dibenzo[b,d] pyran-9-one)
Nicomorphine (3,6-dinicotinylmorphine)
Noracymethadol (α-3-acetoxy-6-methylamino-4,4-diphenylheptane)
Norlevorphanol (−)-3-hydroxymorphinan
Normethadone (6-dimethylamino-4,4-diphenyl-3-hexanone)
Normorphine (demethylmorphine)
Norpipanone (4,4-diphenyl-6-piperidino-3-hexanone)
Oxycodone (14-hydroxydihydrocodeinone)
Oxymorphone (14-hydroxydihydromorphinone)
PEPAP (1-phenethyl-4-phenyl-4-piperidinol acetate (ester))
Pethidine (1-methyl-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Pethidine-intermediate-A (4-cyano-1-methyl-4-phenylpiperidine)
Part 3—continued

Pethidine-intermediate-B  (4-phenylpiperidine-4-carboxylic acid ethyl ester)
Pethidine-intermediate-C  (1-methyl-4-phenylpiperidine-4-carboxylic acid)
Phenadoxone  (6-morpholino-4,4diphenyl-3-heptanone)
Phenampromide  (N-(1-methyl-2-piperidinoethyl) propionanilide)
Phenazocine  (2’-hydroxy-5,9-dimethyl-2-phenethyl-6,7-benzo- morphan)
Phendimetrazine  (3,4-dimethyl-2-phenylmorpholine)
1-phenethyl-4-phenyl-4-piperidinol.
Phenmetrazine  (3-methyl-2-phenylmorpholine)
Phenomorphan  (3-hydroxy-N-phenethylmorphinan)
Phenoperidine  (1-(3-hydroxy-3-phenylpropyl)-4-phenylpiperidine-4-carboxylic acid ethyl ester)
Piminodine  (4-phenyl-1-(3-phenylaminopropyl)piperidine-4-carboxylic acid ethyl ester)
Piritramide  (1-(3-cyano-3,3-diphenylpropyl)-4-(1-piperidino) piperidine-4-carboxylic acid amide)
Proheptazine  (1,3-dimethyl-4-phenyl-4-propionoxyazacycloheptane)
Properidine  (1-methyl-4-phenylpiperidine-4-carboxylic acid isopropyl ester)
Racemethorphan  ((±)-3-methoxy-N-methylmorphinan)
Racemoramide  ((±) -4- [2-methyl-4-oxo-3, 3-diphenyl-4-(1-pyrrolidinyl) butyl] morpholine)
Racemorphan  ((±)-3-hydroxy-N-methylmorphinan)
Remifentanil  (1-(2-methoxycarbonyl-ethyl)-4-(phenylpropionyl- amino)piperidine-4-carboxylic acid methyl ester)
Sufentanil  (N-[4-((methoxymethyl)-1-[2-(2-thienyl)ethyl]-4-piperidyl] propionanilide)
Tapentadol  (3-[(1R,2R)-3-(dimethy lamino)-1-ethyl-2-methylpropyl]phenol hydrochloride)
Thebacon  (acetyldihydrocodeinone)
Thebaine
Part 3—continued

**Thiofentanyl** (N-[1-[2-(2-thienyl)ethyl]-4-piperidyl]propionanilide)

**Tilidine** ((±)-ethyl trans-2-(dimethylamino)-1-phenyl-3-cyclohexene-1-carboxylate)

**Trimeperidine** (1,2,5-trimethyl-4-phenyl-4-propionoxypiperidine).


Part 3—continued

Schedule 2 Part 3 clause 1 Tapentadol: inserted, on 1 May 2012, by clause 3 of the Misuse of Drugs (Classification of Tapentadol) Order 2011 (SR 2011/247).

2 The isomers of the substances mentioned in this Part whenever the existence of such isomers is possible within the specific chemical designation.

3 The esters and ethers of the substances mentioned in this Part and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.

4 The salts of the substances mentioned in this Part and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4.
Schedule 3

Class C controlled drugs

Part 1

1 **Cannabis fruit**

**Cannabis plant** (whether fresh, dried, or otherwise)—that is, any part of any plant of the genus *Cannabis* except a part from which all the resin has been extracted

**Cannabis seed**

**Catha edulis plant**

**Coca leaf**—that is, the leaf of any plant of any species of the genus *Erythroxylon*, except a leaf from which all ecygonine, cocaine, and any other ecygonine alkaloids have been removed.


2 The following substances:

**BZP** (1-benzylpiperazine or A2 benzylpiperazine or N-benzylpiperazine (1-benzyl-1,4-diazacyclohexane))

**TFMPP** (1-(3-trifluoromethylphenyl)piperazine or N-(3-trifluoromethylphenyl)piperazine)

**pFPP** (1-(4-fluorophenyl)piperazine)

**MeOPP** (1-(4-methoxyphenyl)piperazine)

**mCPP** (1-(meta-chlorophenyl)piperazine) or 1-(3-chlorophenyl)piperazine)

**MBZP** (1-methyl-4-benzylpiperazine).


3 The isomers of the substances mentioned in clause 2 whenever the existence of such isomers is possible within the specific chemical designation.

Part 1—continued

4 The esters and ethers of the substances mentioned in clause 2 and the esters and the ethers of the isomers mentioned in clause 3 whenever the existence of such esters or ethers is possible.


5 The salts of the substances mentioned in clause 2 and the salts of the isomers, esters, and ethers mentioned in clause 3 or 4.


6 Substances containing any proportion of a substance mentioned in clause 2, 3, 4, or 5.


Part 2

Codeine (3-methylmorphine); its isomers, esters, and ethers, if any; its salts, and the salts of its isomers, esters, or ethers, if any; and any substance, preparation or mixture containing any proportion of the said substance or of any such isomer, ester, ether, or salt, other than a preparation or mixture named or described in Part 6

Dihydrocodeine; its isomers, esters, and ethers, if any; its salts, and the salts of its isomers, esters, or ethers, if any; and any substance, preparation, or mixture containing any proportion of the said substance or of any such isomer, ester, ether, or salt, other than a preparation or mixture named or described in Part 6

Propoxyphene (α-4 (N, N-dimethylamino)-1, 2-diphenyl-3-methyl-2-propionoxybutane); its isomers, esters, and ethers, if any; its salts and the salts of its isomers, esters, or ethers, if any; except in preparations of propoxyphene described in clause 5A of Part 5.


Schedule 3 Part 2 Propoxyphene: substituted, on 20 December 1984, by clause 2(1) of the Misuse of Drugs Order (No 2) 1984 (SR 1984/315).
Part 3

1 The following substances, namely:
   - Acetyldihydrocodeine
   - Ethylmorphine (3-ethylmorphine)
   - Nicocodine (6-nicotinylcodeine)
   - Nicodicodine (6-nicotinylidihydrocodeine or nicotinic acid ester of dihydrocodeine)
   - Norcodeine (N-demethylcodeine)
   - Pholcodine (morpholinylethylmorphine)
   - Propiram (N-(1-methyl-2-piperidinoethyl)-N-2-pyridylpropionamide).


2 The isomers of the substances mentioned in this Part whenever the existence of such isomers is possible within the specific chemical designation.

3 The esters and ethers of the substances mentioned in this Part and the esters and the ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.

4 The salts of the substances mentioned in this Part and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4, other than a preparation or mixture named or described in Part 6.

6 [Repealed]

   Schedule 3 Part 3 clause 6: repealed, on 8 September 2011, by section 9(1) of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).
Part 4

1 The following substances, namely:

Allobarbital (5,5-diallylbarbituric acid)
Amobarbital (5-ethyl-5-(3-methylbutyl) barbituric acid)
Buprenorphine (17-cyclopropylmethyl-7,8-dihydro-7-(1-hydroxy-1,2, 2-trimethylpropyl) -6-0-methyl-6, 14-ethano-17-normorphine)
Butalbital (5-allyl-5-isobutylbarbituric acid)
Butobarbitone (5-butyl-5-ethylbarbituric acid)
Cyclobarbital (5-(1-cyclohexen-1-yl)-5-ethylbarbituric acid)
Glutethimide (2-ethyl-2-phenylglutarimide)
Ketamine (2-(2-chlorophenyl)-2-(methylamino)-cyclohexanone)
Nealbarbitone (5-allyl-5-neopentylbarbituric acid)
Pentobarbital (5-ethyl-5-(1-methylbutyl) barbituric acid)
Secbutabarbital (5-sec-butyl-5-ethylbarbituric acid)
Secobarbital (5-allyl-5-(1-methylbutyl) barbituric acid)
Vinylbital (5-(1-methylbutyl)-5-vinylbarbituric acid).

Schedule 3 Part 4 clause 1 Ketamine: inserted, on 1 December 2010, by clause 3 of the Misuse of Drugs (Presumption of Supply—Ketamine) Order 2009 (SR 2009/256)

2 The isomers of the substances mentioned in this Part whenever the existence of such isomers is possible within the specific chemical designation.
Part 4—continued

3 The esters and ethers of the substances mentioned in this Part and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.

4 The salts of the substances mentioned in this Part and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, or clause 4, except a mixture of a derivative of barbituric acid named or described in clause 1 compounded with 1 or more other pharmacologically active ingredients not named or described in clause 1.


Part 5

1 The following substances, namely:
   Alprazolam
   Amfepramone (2-(diethylamino) propiophenone)
   Aminorex
   Barbital (5,5-diethylbarbituric acid)
   Bromazepam
   Brotizolam
   Camazepam
   Chlordiazepoxide
   Clobazam
   Clonazepam
   Clorazepate
   Clotiazepam
   Cloxazolam
   Delorazepam
   Diazepam
   Estazolam
### Part 5—continued

- **Ethchlorvynol** (ethyl-2-chlorovinylethynyl-carbinol)
- **Ethinamate** (1-ethynlycyclohexanol carbamate)
- **Ethyl loflazepate**
- **Fludiazepam**
- **Flunitrazepam**
- **Flurazepam**
- **Halazepam**
- **Haloxazolam**
- **Ketazolam**
- **Loprazolam**
- **Lorazepam**
- **Lormetazepam**
- **Mazindol** (5-(4-chlorophenyl)-2, 5-dihydro-3H-imidazo [2, 1-a]-isoindol-5-ol)
- **Medazepam**
- **Meprobamate** (2-methyl-2-propyl-1,3-propanediol dicarbamate)
- **Methylphenobarbital** (5-ethyl-1-methyl-5-phenylbarbituric acid)
- **Methylprylon** (3,3-diethyl-5-methylpiperidine-2,4-dione)
- **Midazolam**
- **Nimetazepam**
- **Nitrazepam**
- **Nordazepam**
- **Oxazepam**
- **Oxazolam**
- **Pemoline**
- **Phenobarbital** (5-ethyl-5-phenylbarbituric acid)
- **Phentermine** (2-amino-2-methyl-1-phenylpropane)
- **Pinazepam**
- **Pipradrol** (1,1-diphenyl-1-(2-piperidyl)methanol)
- **Prazepam**
- **SPA** ((−)-1-dimethylamino-1,2-diphenylethane)
Part 5—continued

Temazepam

Tetrazepam

Triazolam.


Schedule 3 Part 5 clause 1 Aminorex: inserted, on 30 May 2003, by clause 6 of the Misuse of Drugs (Changes to Controlled Drugs) Order 2003 (SR 2003/47).


Schedule 3 Part 5 clause 1 Ephedrine: repealed, on 8 September 2011, by section 9(2) of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).


Schedule 3

Misuse of Drugs Act 1975

Reprinted as at 1 August 2012

Part 5—continued


Schedule 3 Part 5 clause 1 Mazindol: substituted, on 20 December 1984, by clause 2(2) of the Misuse of Drugs Order (No 2) 1984 (SR 1984/315).


Schedule 3 Part 5 clause 1 Pemoline: inserted, on 30 May 2003, by clause 6 of the Misuse of Drugs (Changes to Controlled Drugs) Order 2003 (SR 2003/47).


Schedule 3 Part 5 clause 1 Pseudoephedrine: repealed, on 8 September 2011, by section 9(2) of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).


Part 5—continued


2 The isomers of the substances mentioned in this Part whenever the existence of such isomers is possible within the specific chemical designation.

3 The esters and ethers of the substances mentioned in this Part and the esters and ethers of the isomers mentioned in clause 2 whenever the existence of such esters or ethers is possible.

4 The salts of the substances mentioned in this Part and the salts of the isomers, esters, and ethers mentioned in clause 2 or clause 3.

5 Mixtures of a derivative of barbituric acid named or described in Part 4 compounded with 1 or more other pharmacologically active ingredients not named or described in Part 4.


5A Preparations of propoxyphene, its isomers, esters, and ethers, if any, its salts, and the salts of its isomers, esters, or ethers, if any, for oral use containing not more than the equivalent of 135 milligrams of propoxyphene base per dosage unit or with a concentration of not more than 2.5% in undivided preparations, being preparations whereof none of the other ingredients is a substance named or described in Schedules 1 or 2 or in Parts 1 to 5 of this schedule.

Schedule 3 Part 5 clause 5A: substituted, on 20 December 1984, by clause 2(3) of the Misuse of Drugs Order (No 2) 1984 (SR 1984/315).

6 Substances containing any proportion of a substance mentioned in clause 1, clause 2, clause 3, clause 4, clause 5 or clause 5A, other than a preparation or mixture named or described in Part 6.
Part 5—continued


Part 6

The following preparations and mixtures, namely:

(a) preparations containing any proportion of the following substances or of any salt of any such substance, namely, acetyldihydrocodeine, codeine, dihydrocodeine, ethylmorphine, and pholcodine when:
   (i) compounded with 1 or more other pharmacologically active ingredients in such a way that the substance cannot be recovered by readily applicable means or in a yield which would constitute a risk to health; and
   (ii) containing not more than 100 milligrams of the substance in each dosage unit and with a concentration of not more than 2.5% in undivided preparations:

(aa) preparations containing a derivative of barbituric acid named or described in Part 4 or Part 5, in solutions containing not more than 0.5% of that derivative of barbituric acid:

(b) preparations of cocaine containing not more than 0.1% of cocaine base, being preparations compounded with 1 or more other pharmacologically active ingredients (none of which are substances named or described in Schedules 1 or 2 or in Parts 1 to 5 of this schedule) in such a way that the preparation has no, or a negligible, risk of abuse, and in such a way that the cocaine cannot be recovered by readily applicable means or in a yield which would constitute a risk to health:

(c) preparations of difenoxin containing, per dosage unit, not more than 0.5 mg of difenoxin and a quantity of atropine sulphate equivalent to at least 5% of the dose of difenoxin:

(d) preparations of opium or morphine containing not more than 0.2% of morphine, being preparations compounded with 1 or more other pharmacologically active ingredients (none of which are substances named or described in Schedules 1 or 2 or in Parts 1 to 5 of this schedule) in such a way that the opium or the morphine, as the case may be, cannot be recovered by
Part 6—continued

readily applicable means or in a yield which would constitute a risk to health:

(c) single dosage units of diphenoxylate containing in each unit not more than 2.5 milligrams of diphenoxylate calculated as base and not less than 25 micrograms of atropine sulphate:

(f) liquid preparations of diphenoxylate containing, in each millilitre, not more than 0.5 milligrams of diphenoxylate calculated as base and not less than 5 micrograms of atropine sulphate:

(ff) preparations of propiram containing not more than 100 mg of propiram per dosage unit and compounded with at least the same amount of methylcellulose:

(g) ipecacuanha and opium powder containing 10% of opium in powder and 10% of ipecacuanha root in powder intimately mixed with finely powdered lactose:

(h) mixtures containing not more than 1 of the preparations specified in paragraphs (a) to (g), being mixtures whereof none of the other ingredients is a substance named or described in Schedules 1 or 2 or in Parts 1 to 5 of this schedule.


Part 7


Amphetamine analogues, in which the 1-amino-2-phenylethane nucleus carries any of the following radicals, either alone or in combination:

(a) 1 or 2 alkyl radicals, each with up to 6 carbon atoms, attached to the nitrogen atom:

(b) 1 or 2 methyl radicals, or an ethyl radical, attached to the carbon atom adjacent to the nitrogen atom:

(c) a hydroxy radical, attached to the carbon atom adjacent to the benzene ring:

(d) any combination of up to 5 alkyl radicals and/or alkoxy radicals and/or alkylamino radicals and/or alkylthio radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or
halogen radicals and/or nitro radicals and/or amino radicals, attached to the benzene ring.

**Pethidine analogues**, in which a 4-phenylpiperidine nucleus carries any of the following radicals, either alone or in combination:

(a) an alkyl radical, with up to 6 carbon atoms, attached to the nitrogen atom:

(b) a phenalkyl radical, with up to 12 carbon atoms, attached to the nitrogen atom:

(c) a phenalkyl radical, as in paragraph (b), with 1 or more alkyl radicals, each with up to 6 carbon atoms, attached to the benzene ring in the phenalkyl radical:

(d) an alkylcarbonyloxy or alkoxy carbonyl or hydroxy radical, with up to 6 carbon atoms, attached to the 4 position in the piperidine ring:

(e) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to the benzene ring.

**Phencyclidine analogues**, being chemical compounds with the 1-alkylamino-1-arylcyclohexane structure, with any combination of the following alkylamino and aryl radicals:

(a) the alkylamino radical is 1-piperidinyl, 1-pyrrolidinyl, 4-morpholinyl, or any other radical with up to 6 carbon atoms in the alkyl portion:

(b) the aryl radical is phenyl, thienyl, pyridinyl, or pyrrolidinyl:

(c) the aryl radical, as described in paragraph (b), carries any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals.

**Fentanyl analogues**, in which the N-[1-(2-phenethyl)-4-piperidyl]aniline nucleus has additional radicals, either alone or in combination, attached as follows:

(a) an acetyl, propionyl, butenoyl or butanoyl radical, attached to the aniline nitrogen atom:

(b) 1 or more alkyl radicals, with up to 10 carbon atoms in total, attached to the ethyl moiety:
Part 7—continued

(c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the benzene rings.

Methaqualone analogues, in which the 3-arylquinazolin-4-one nucleus has additional radicals, either alone or in combination, attached as follows:

(a) an alkyl radical, with up to 6 carbon atoms, attached at the 2 position:
(b) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to each of the aryl rings.

DMT (dimethyltryptamine) analogues, in which the 3-(2-aminoethyl)indole nucleus has additional radicals, either alone or in combination, attached as follows:

(a) 1 or 2 alkyl radicals, each with up to 6 carbon atoms, including cyclic radicals, attached to the amino nitrogen atom:
(b) 1 or 2 methyl groups, or an ethyl group, attached to the carbon atom adjacent to the amino nitrogen atom:
(c) any combination of up to 5 alkyl radicals and/or alkoxy radicals (each with up to 6 carbon atoms, including cyclic radicals) and/or halogen radicals, attached to the benzene ring.

Schedule 3 Part 7 Amphetamine analogues paragraph (d): amended, on 9 August 2011, by section 9(3) of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).


Schedule 4

Precursor substances


Part 1

1 The following substances:
   Acetic anhydride
Part 1—continued

N-acetylanthranilic acid
Ergometrine
Ergotamine
Isosafrole
Lysergic acid
3, 4-methylenedioxyphenyl-2-propanone
1-phenyl-2 propanone
Piperonal
Potassium permanganate
Safrole.

Schedule 4 Part 1 clause 1 ephedrine: repealed, on 8 September 2011, by section 10 of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).
Schedule 4 Part 1 clause 1 Pseudoephedrine: repealed, on 8 September 2011, by section 10 of the Misuse of Drugs Amendment Act (No 2) 2011 (2011 No 54).

2 The salts of the substances listed in clause 1 whenever the existence of such salts is possible.
Part 2

1  The following substances:
   Acetone
   Anthranilic acid
   Ethyl ether
   Hydrochloric acid
   Methyl ethyl ketone
   Phenylacetic acid
   Piperidine
   Sulphuric acid
   Toluene.

   Schedule 4 Part 2 clause 1 Acetic anhydride: repealed, on 22 June 2005, by section 21(b) of the Misuse of Drugs Amendment Act 2005 (2005 No 81).


2  The salts of the substances listed in clause 1 (other than the salts of hydrochloric acid and of sulphuric acid) whenever the existence of such salts is possible.

Part 3

1  The following substances:
   Ephedrine
   Pseudoephedrine.

2  The salts of the substances listed in clause 1 whenever the existence of such salts is possible.